Analyst Says CA Pharma Underappreciated by Investors
Research Report
Analyst's Target Price for Biotech Massively Higher Than Current Price
Research Report
Study Shows 93% Cough Suppression With Co.'s Drug
Could This Stock Be the Next Bellus Cough Treatment?
Contributed Opinion
LA Biotech Unveils New Patented Nicotinamide Riboside Chloride
Research Report
Healthcare AI Company Achieves Key Milestones and Secures New Partnerships
Biopharma Co. Reports Strong FQ224 Results Driven
Research Report
Texas Biotech Announces Plans for Preclinical Obesity Studies
Research Report
Bio-Path Holdings Inc. (BPTH:NASDAQ) recently announced its progress in its cancer clinical trials and plans to begin preclinical obesity studies, according to a Roth MKM research note. AI Health Stock Heading Higher Expert Says
Contributed Opinion
Technical Analyst Clive Maund gives an update on Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) as he believes "something is going on" and the stock may be heading higher. California Biotech Reports Positive Phase 3 Results
Research Report
"Along with the significantly lower pill burden compared to other phosphate binders, we believe the superior tolerability may be attributable to OLC's nanoparticle technology," noted an H.C. Wainwright & Co. research note, regarding Unicycive Therapeutics Inc.'s (UNCY:NASDAQ) trial of oxylanthanum carbonate (OLC) for the treatment of hyperphosphatemia in chronic kidney disease (CKD) patients. Chicago Alt. Medicine Co. Announces US$50M Share Repurchase Program
Research Report
In a Roth MKM research note, analyst Nick Anderson noted that Verano Holdings Corp. (VRNO:CSE; VRNOF:OTCQX) was well-positioned to generate increasing cash flow. Clean Tech Subsidiary Finds Manufacturer for Wound Solution
BioLargo Inc. (BLGO:OTCQB) announced that subsidiary Clyra Medical Technologies Inc. has selected a company to support the manufacturing of its medical products, including its surgical wound irrigation solution, Bioclynse. See why one nonprofit group says the rate of healthcare-associated infections has remained high since the pandemic.Is This Pharma Co. the Next Eli Lilly?
Nervgen Pharma Corp. (NGEN:TSX.V; NGENF:OTCQX) is making significant strides in the field of nerve damage and spinal cord injury treatments. Find out about the company's future plans and why Chen Lin of What is Chen Buying? What is Chen Selling? said he believes Nervgen could potentially become the next Eli Lilly.Positive Phase 2 Clinical Trial Results Announced for Drug Treating Idiopathic Hypersomnia
Zevra Therapeutics Inc. (ZVRA:NASDAQ), a company specializing in rare disease therapeutics, has announced positive final results from its Phase 2 clinical trial evaluating the safety and tolerability of KP1077 for treating idiopathic hypersomnia.Rare Disease Co. Presents Positive Phase 2 KP1077 Data
Research Report
Zevra Therapeutics Inc. (ZVRA:NASDAQ) recently presented positive final results from its Phase 2 trial evaluating KP1077 in idiopathic hypersomnia (IH) patients at the SLEEP 2024 conference, according to a Roth MKM research note. 
Streetwise Key Charts
